Naltrexone and Nalmefene as Modern Psychopharmacotherapy for Alcohol Use Disorder: Modulation of Opioid Receptors and Neurobiological Pathways of Alcohol Action
Maciej Rząca, Mateusz Sroka, Katarzyna Fus, Dawid Ślebioda, Rozalia Kozinska, Mateusz Chmiela, Agnieszka Chłopaś-Konowałek · 2026
Read Naltrexone and Nalmefene as Modern Psychopharmacotherapy for Alcohol Use Disorder: Modulation of Opioid Receptors and Neurobiological Pathways of Alcohol Action by Maciej Rząca, Mateusz Sroka, Katarzyna Fus, Dawid Ślebioda, Rozalia Kozinska, Mateusz Chmiela, Agnieszka Chłopaś-Konowałek (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13297373.txt.
Description
Two established medicines for alcohol dependence get a side-by-side appraisal in a 2026 review led by Maciej Rząca and colleagues. The authors weigh naltrexone and nalmefene, drugs that act on opioid receptors, and ask how each one performs against drinking outcomes that matter in practice.
Outcomes centered on total alcohol consumption and monthly heavy drinking days, alongside safety, side effects, dropout, and dosing convenience. Nalmefene, taken only when needed, cut both measures, with gains appearing within the first month and holding through follow-up. Naltrexone performed comparably in pooled analyses, and its long-acting injection eased dosing for some patients. Common side effects were mild, mainly nausea and dizziness.
Catalog record
| CREATOR | Maciej Rząca, Mateusz Sroka, Katarzyna Fus, Dawid Ślebioda, Rozalia Kozinska, Mateusz Chmiela, Agnieszka Chłopaś-Konowałek |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 74557 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |